Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about how the company is differentiating itself in the crowded immuno-oncology development space. Vaximm is also looking for pharma partners with checkpoint inhibitors to advance its oral T-cell immunotherapies.
The company’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be adapted to target a wide range of cancer-related antigens. Vaximm’s most advanced compound, VXM01, is in Phase I/IIa studies with data expected in early 2017.
Schroff was appointed CEO of Vaximm in September this year; previously he was CEO of Mologen AG, a publicly-traded German biotech company.
Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Dr. Matthias Schroff – CEO, VAXIMM